New Once-Daily pill aims to tame ADHD symptoms in korean youth

NCT ID NCT07678827

Not yet recruiting Disease control Sponsor: Alvogen Korea Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether viloxazine extended-release capsules, taken once daily, can safely reduce ADHD symptoms in Korean children and adolescents aged 6 to 17. Participants receive either the drug or a placebo for 8 weeks, with doses adjusted based on response. The study measures changes in ADHD rating scores to see if the medication works better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: viloxazine extended-release capsules
What this could lead to: If successful, this could provide a new once-daily medication option for managing ADHD symptoms in Korean children and adolescents.
What could go wrong: This is a bridging trial with a relatively small sample size (156 participants) and short duration (8 weeks), so results may not generalize to broader populations or long-term use. Side effects are possible, as with any medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD ATTENTION DEFICIT HYPERACTIVITY DISORDER

Contacts and locations

Locations

Seoul National University Hospital

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.